These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 15065530

  • 1. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
    Morozov SV, Tsodikova OM, Isakov VA, Gushchin AE, Shipulin GA.
    Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
    Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S.
    Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
    [Abstract] [Full Text] [Related]

  • 3. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S.
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [Abstract] [Full Text] [Related]

  • 4. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
    Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ.
    Aliment Pharmacol Ther; 2012 Apr; 35(7):810-8. PubMed ID: 22324425
    [Abstract] [Full Text] [Related]

  • 6. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J.
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [Abstract] [Full Text] [Related]

  • 7. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P, Katz PO, Chen Y, Sostek M.
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [Abstract] [Full Text] [Related]

  • 8. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
    [Abstract] [Full Text] [Related]

  • 9. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T.
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [Abstract] [Full Text] [Related]

  • 10. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 11. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K, Lind T, Wilder-Smith C.
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [Abstract] [Full Text] [Related]

  • 12. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
    Li ZS, Zhan XB, Xu GM, Cheng NN, Liao Z.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
    [Abstract] [Full Text] [Related]

  • 13. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
    Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, Treiber G.
    Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
    [Abstract] [Full Text] [Related]

  • 14. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U.
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [Abstract] [Full Text] [Related]

  • 15. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
    Robinson M.
    Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M, Togawa J, Takahashi K, Yoneda M, Fujisawa N, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H.
    J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
    [Abstract] [Full Text] [Related]

  • 17. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
    Lee YC, Lin JT, Wang HP, Chiu HM, Wu MS.
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
    [Abstract] [Full Text] [Related]

  • 18. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T.
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
    [Abstract] [Full Text] [Related]

  • 19. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.
    Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N.
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1301-7. PubMed ID: 12144580
    [Abstract] [Full Text] [Related]

  • 20. CYP2C19 genotype and the PPIs--focus on rabeprazole.
    Lim PW, Goh KL, Wong BC.
    J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.